NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 25 February 2010 The HORIZONS-AMI trial assessed high-risk patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). One year follow-up data to this study suggest […]
Category Archives: Cardiovascular disease
NPC Archive Item: NICE publishes guidance on VTE prevention in adult patients in hospital
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 8 February 2010 NICE has published new guidance which aims to reduce the risk of venous thromboembolism (VTE) in patients admitted to hospital, including day case patients. VTE includes […]
NPC Archive Item: Dabigatran etexilate▼ is as effective as warfarin for the short term management of acute venous thromboembolism
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 3 February 2010 In the RE-COVER trial (n=2,564), dabigatran etexilate▼ 150mg twice daily for six months was found to be as effective as dose-adjusted warfarin in preventing recurrent venous […]
NPC Archive Item: Use of triple antithrombotic therapy increases the risk of bleeding four times post MI
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 25 January 2010 An observational study found that, in patients with first-time MI, the risk of hospital admission for bleeding was four times higher in those taking triple antithrombotic […]
NPC Archive Item: More data suggest aspirin is ineffective for primary prevention in patients with diabetes
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 25 January 2010 This meta-analysis found aspirin did not statistically significantly reduce the risk of major CV events, CV mortality or all-cause mortality in people with diabetes and no […]
NPC Archive Item: Apixaban vs. enoxaparin as thromboprophylaxis in knee replacement surgery
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 22 January 2010 In a non-inferiority design, ADVANCE-1 found that results for oral apixaban were similar to s.c. LMWH enoxaparin 30 mg twice daily (not non-inferior) for a primary […]
NPC Archive Item: HEAAL suggests that a higher, unlicensed dose of losartan may have some benefits over the standard dose in heart failure
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 15 January 2010 The HEAAL study compared 50mg and 150mg daily doses of losartan in people with heart failure intolerant of ACE inhibitors. It suggested that the (unlicensed) higher […]
NPC Archive Item: Observational study of hypoglycaemic drugs has limitations
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 15th January 2010 Compared with metformin monotherapy, the fully adjusted analysis in this UK cohort study found no increased risk of heart failure or myocardial infarction with pioglitazone▼ or […]
NPC Archive Item: Cardiovascular outcomes and mortality in patients using clopidogrel with a PPI: more data
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 10 December 2009 A large observational study finds no conclusive evidence for a clinically relevant drug interaction between clopidogrel and PPIs in elderly patients after percutaneous coronary intervention or […]
NPC Archive Item: Darusentan as an add-on in treatment-resistant hypertension
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 9 December 2009, A phase III randomised controlled trial demonstrated that darusentan reduced systolic/diastolic blood pressure by about 10/5mmHg compared with placebo in patients with treatment-resistant hypertension, but was […]